Diabetes management intervention studies: lessons learned from two studies

Bettina Petersen 1, Iris Vesper 1, Bernhild Pachwald 1, Nicole Dagenbach 1, Sina Buck 2*, Delia Waldenmaier 2 and Lutz Heinemann 3

Abstract

Introduction: Several clinical studies investigated improvements of patient outcomes due to diabetes management interventions. However, chronic disease management is intricate with complex multifactorial behavior patterns. Such studies thus have to be well designed in order to allocate all observed effects to the defined intervention and to exclude effects of other confounders as well as possible.

This article aims to provide challenges in interpreting diabetes management intervention studies and suggests approaches for optimizing study implementation and for avoiding pitfalls based on current experiences.

Main body: Lessons from the STeP and ProValue studies demonstrated the difficulty in medical device studies that rely on behavioral changes in intervention group patients. To successfully engage patients, priority should be given to health care professionals being engaged, operational support in technical issues being available, and adherence being assessed in detail.

Another difficulty is to avoid contamination of the control group with the intervention; therefore, strict allocation concealment should be maintained. However, randomization and blinding are not always possible. A limited effect size due to improvements regarding clinical endpoints in the control group is often caused by the Hawthorne effect. Improvements in the control group can also be caused with increased attention paid to the subjects. In order to reduce improvements in the control group, it is essential to identify the specific reasons and adjust study procedures accordingly. A pilot phase is indispensable for this. Another option is to include a third study arm to control for enhanced standard of care and study effects. Furthermore, retrospective data collection could be a feasible option.

Adaptive study designs might reduce the necessity of a separate pilot study and combine the exploratory and confirmatory stages of an investigation in one single study.

Conclusion: There are several aspects to consider in medical device studies when using interventions that rely on changes in behavior to achieve an effective implementation and significant study results. Improvements in the control group may reduce effect sizes and limit statistical significance; therefore, alternatives to the traditional randomized controlled trials may be considered.

Keywords: Diabetes, Study performance, Behavior-based, Medical device studies, Adaptive study design, Study effect, Randomized controlled trials, ProValue, STeP

* Correspondence: sina.buck@idt-ulm.de
1 Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Lise-Meitner-Strasse 8/2, 89081 Ulm, Germany
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Patients with diabetes require a life-long treatment that is not limited to a standardized intake of drugs, but requires a more complex disease management. In particular, type 1 diabetes management involves frequent treatment decisions like adjustment of insulin doses depending on the current glucose status, meal intake, and physical activity level. This requires the use of medical devices, adequate handling by the patient, and translation of the measurement results into appropriate therapeutic decisions. Health care professionals (HCPs) support patients with regular monitoring of markers of glucose control and adjustment of the treatment plan. These factors have a complicated interaction with one another to influence the achievement of a therapeutic goal. If individual components of diabetes management are investigated, e.g., in a clinical study, this interaction has to be taken into account. For example, frequent use of a CGM system and adequate interpretation of glucose values will more likely lead to improvements in diabetes management [1].

Therapeutic improvements that are observed as a result of device usage are not driven by the device itself, but by the behavioral changes the device enables. In clinical studies with medical devices for diabetes management, behavioral changes of study participants, not only those planned for the intervention group, but also unintended changes in control group participants, as well as those of the HCPs, should be taken into account and adequately considered in study design, implementation, and analysis.

Over the last several years, a number of studies have been published that investigated improvements in patient outcomes driven by interventions in their diabetes management with medical devices [2–16].

The Structured Testing Program (STeP) study and the two ProValue studies are examples of studies in which diabetes management interventions on clinical outcomes were investigated [17, 18]. All of these studies were multicenter cluster randomized controlled trials (RCTs) with the primary outcome being improvements in glucose control (HbA1c reduction) in patients with type 2 diabetes.

In the STeP study, subjects in the intervention group performed structured self-monitoring of blood glucose (SMBG) and received enhanced care, while subjects in the control group received standard of care. In the ProValue studies, two levels of ambulatory care, namely diabetes specialized practices (first ProValue study) and general medical practices (second ProValue study), were examined. The ProValue studies also had an identical study design, where subjects in the intervention group used an integrated Personalized Diabetes Management (iPDM) system to support their diabetes therapy while subjects in the control group were to receive standard of care. The primary outcome was an improvement in glycemic control of participants using the iPDM tools compared to the subjects in the control group.

The STeP and the ProValue studies reported significant differences in the reductions in HbA1c between the intervention and control groups; however, considerable improvements in glucose control were observed in the control groups as well [3, 19, 20]. Improvements in the control group reduced the size of the effect of the intervention in these studies. Similar outcomes were observed in other studies, which report conservative or weakened between-group differences due to improvements in the control group [6, 11, 14, 21]. Therefore, solely the recruitment to a clinical trial, independent of the interventions, resulted in improvements in HbA1c [22]. When designing an interventional study, such effects have to be taken into account; otherwise, the observed effects cannot be attributed to the defined intervention due to the profound effects of confounding factors. This is especially important when including behavioral interventions, as comprehensive support of HCPs is essential to utilize the full potential of the intervention.

This article aims to provide challenges in interpreting diabetes management intervention studies gained from the STeP and ProValue studies and suggests approaches for optimizing study implementation and for avoiding pitfalls for further studies with similar medical devices.

Study implementation
Engaging participants in the intervention group
A major difficulty in intervention studies that rely on behavioral changes is to ensure that the intervention triggers the desired effect (Table 1).

While in drug studies an intervention is defined by a given medication scheme that the participants simply have to follow, behavioral changes cannot be triggered that straightforward [23, 24].

There is no single intervention strategy to guarantee intervention adherence of all participants. Furthermore, a distinction between unintentional and intentional non-adherence should be taken into account. Whereas unintentional non-adherence depends on modifiable factors like poor understanding of the treatment or low health literacy or numeracy, in intentional non-adherence, participants rationally decide to not adhere by weighing the benefits and risk of following an intervention [25].

A set of key factors influencing attempts to improve participants’ unintentional non-adherence include a clear and effective communication between HCP and participant as well as realistic assessments of participants’ health literacy and knowledge. Health literacy is essential to the ability to adhere to study intervention as well as the ability to remember the details of the
recommendations made to participants during visits influences the adherence. Thus, the explanation of the specific steps of the study regimen, review of the most important details, and written instructions may increase adherence. Furthermore, the risk of non-adherence is reduced with a more familiar relationship between HCP and participant. This enables HCPs to understand participants’ beliefs, attitudes, subjective norms, cultural context or social supports, and other relevant elements that are crucial for patient’s adherence [26, 27].

Many different behavior change techniques are already included in the standard of care in diabetes therapy, such as providing feedback on HbA1c levels and setting personal goals [25, 28].

In the ProValue studies, for example, the diabetes management intervention comprised a blood glucose meter and the corresponding software. Subjects in the intervention group had to perform structured SMBG with an individualized testing regimen selected by the treating physicians. This selection, as well as treatment adjustments, was supported by the diabetes management software. To ensure optimal engagement of the involved HCPs with a leading role in the implementation of the intervention, numerous local investigator meetings were organized. During these investigator meetings, HCPs of intervention group sites were trained by the coordinating investigator and the sponsor’s medical advisor in the use and concept of the diabetes management program. These meetings also enabled an exchange of experiences and individual patient cases could be discussed. HCPs could thus find a way to implement the iPDM into their daily practice and individual treatment patterns, and they were motivated to appropriately use the program. It was expected that this confidence and commitment of the HCPs would increase subjects’ compliance as well [29]. Inherently, the investigator meetings and the

---

**Table 1** Crucial aspects to consider in clinical studies with medical devices that rely on behavioral changes and options to reduce potential limitations including their challenges

| Aspects to consider                      | Options to reduce limitations                                                                 | Challenges                                            |
|-----------------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------|
| **Engaging participants in the intervention group** | Optimal engagement of involved HCPs:  
  • Investigator meetings  
  • Repeated training sessions of study sites  
  • Peer-to-peer review  
  Support in device handling on individual levels:  
  • Training for HCPs  
  • Technical trainers should be familiar with study aims  
  • Visualization of device-based intervention messages for subjects  
  Detailed assessment of adherence:  
  • Questionnaires (e.g., about therapy adaptations, perceptions of tools)  
  • Result analysis of both: “per protocol population” and “intention to treat population” |  • Cost and time expensive  
  • Consider optimal timing of training activities  
  • Cost and time expensive  
  • Consider optimal timing of training activities |  • Adherence to some instructions are difficult to trace |
| Control group management                 | Cluster-randomization  
  Minimum attention to control group  
  Pilot trials  
  Pretest periods  
  Third study arm  
  Use of historical controls; retrospective data collection  
  Using two separate protocols for the two groups  
  Two-stage randomization  
  Adaptive study designs |  • Limited statistical power  
  • Calculated cluster numbers have to be feasible, ethically justifiable, and affordable  
  • Disease management is complex  
  • Standard of care cannot be fully standardized  
  • Standard of care is often less defined and monitored than the interventional treatment  
  • Cost and time expensive  
  • Cost and time expensive  
  • Reduced statistical power → requires more subjects → cost and time expensive  
  • Identification of a suitable control data  
  • Consider progress in treatment standards  
  • Informed consent forms should be well designed to avoid inclusion of interventional aspects  
  • Ethical concern  
  • Changes have to be planned and defined in advance  
  • Implementation of adaptations has yet to be investigated |  |
behavior changes of HCPs varied widely, partly because the initial knowledge and skills in the use of technology already differed between the study sites. Additional attempts for a standardization of handling iPDM would have increased comparability, but would have impaired the real-life aspects and competed with the need for actions individually tailored to each patient. As the desired behavioral changes are not expected to occur in one stroke but rather gradually in the course of the study and with the active use of the iPDM, repeated training sessions of study sites were supportive.

One instrument used in the STeP study was the “peer-to-peer review” that scheduled a review of intervention group patient data and subsequent therapy and advised by an uninvolved practitioner. The independent physician applied the same principles of the iPDM used in the regular study procedures and gave direct feedback to the treating physician on how to intensify or improve therapy adjustments. Even though the iPDM used in ProValue was constructed as an ongoing circle, most improvements were observed rapidly after study start [20]. This should be considered when the optimal timing of training activities has to be determined.

To be able to evaluate whether a behavioral intervention is successful, it is necessary to verify that recommendations have actually been followed. For the ProValue studies, this takes into account whether the HCP makes use of proposals made by the software and whether participants adhere to their HCP’s advices and instructions. While adherence to some instructions like the number of daily SMBG measurements can be assessed easily when device data are downloaded, other instructions like the consideration of SMBG results for insulin dosing decisions or dietary recommendations are difficult to be traced. Information on the intentional use of the intervention might be helpful in subgroup analysis to evaluate the effect of the intervention when completely implemented. In the ProValue studies, this was captured by questionnaires about the perception of the tools among HCPs and participants and by capturing detailed information about therapy adaptations and HCP recommendations. Data to identify and trace potentials and hurdles were available during each stage of the iPDM circle. In this regard, including an analysis of the “per protocol population” that fully adhered to the study intervention procedures is highly recommended in addition to results for the intention to treat population. Bartolo et al., for instance, could not show an advantage of a diabetes management intervention compared to standard care in their study [14]. However, they reported compliance to SMBG of less than approximately 50% in both groups and they reported larger improvements among patients that were more compliant. An inadequate use that did not lead to the intended behavior changes in the study might have been a reason for the limited effects.

However, the introduction of a new medical device is time and energy consuming for HCPs. For example, software like the one used in the ProValue studies is, at least in Germany, not as common as one would expect at the present time, especially among general practitioners. Support in all technical issues should be provided on an individual level by study sponsors, adjusted to the particular knowledge and requirements, on demand and on site. Moreover, to be able to support the study sites in an appropriate and targeted manner, technical trainers have to be familiar with study aims and procedures too.

In addition to technical training for the HCPs, messages from such a digital technology-based intervention have to be conveyed to the patients in a way they can understand. One lesson learned from STeP and ProValue is that visualization is an important factor. In STeP, patients graphically documented their blood glucose levels in a paper tool with color grades, while in ProValue, downloaded data were reported in a traffic light scheme (Figs. 1 and 2). Such visual feedback provides a link between technology, HCPs, and patients and facilitates the implementation of the intervention.

Management of the control group
Another major difficulty in intervention studies that rely on behavioral change is to keep participants in the control group distant from the intervention, i.e., that behavioral changes desired in the intervention group do not occur in the control group as well (Table 1). While in drug studies finding an adequate control (e.g., a placebo) is mostly straightforward, control group design for behavioral studies is complex and the achievement of a truly “inactive” control group that strictly stays with standard care and does not change behavior is almost impossible. Usually, randomization and blinding are the preferred tools, but the implementation is not always feasible.

Adoption of behavioral changes requires an active involvement of both patients and HCPs; blinding is therefore not an option. If HCPs are also part of the intervention, like in STeP and ProValue studies, study personnel which gained knowledge from treating the intervention group subjects could transfer this to those in the control group, at least to a given extent. Thus, cluster-randomization, i.e., randomization of the study sites rather than the individual subjects, is necessary to avoid “contamination” of subjects in the control group [23]. This means cluster-randomization is suitable for interventions that are unlikely to be available for HCPs and patients in the trial [23].

Cluster-randomization, however, limits the possibility to control for differences between the sites, such as their
implementation of standard of care. As the control sites are aware of the intervention done at the intervention sites, there is the risk that they tend to try to improve therapy in control group patients too and are more attentive to patient care than usual.

Statistical power of cluster-randomized studies is limited; they thus require larger sample sizes. Based on the variation between the clusters and the expected effect size, the optimal number of clusters, i.e., study sites, and subjects per cluster can be calculated [30]. However, scheduling the required numbers is often complicated by feasibility, ethical justifiability, and affordability, which may enforce the acceptance of compromises.

A limited effect size due to improvements also in the control group is an often-observed incident, caused by the so-called Hawthorne effect. This effect is attributable to subjects’ knowledge of being part of a study, i.e., being observed and having data collected. This study effect can improve the health status of a subject without any further intervention [31, 32]. Asking questions, for instance, induces rethinking about the current behavior and might induce respective changes [33]. Another reason for improvements in the control group is increased attention paid to the subjects by their HCPs. In principle, this increase in attention should be kept to a minimum; however, in reality, it is difficult to avoid. In addition, an intensive data gathering approach as used in the ProValue studies induces a high engagement of the participating HCPs (and also of the patients in both study groups) leading to improvements in the control group as well [20].

Also, the monitoring effort of clinical research associates (CRAs) regarding study implementation by HCPs, which is an absolutely necessary study procedure, has an impact on study implementation.

Limiting information about the intervention might be a possibility to reduce control group effect. This is not in strict compliance with the guideline for Good Clinical Practice. However, as long as the safety of study participants is paramount, a degree of concealment is accepted by research ethics committees for behavioral intervention studies [34]. According to this, all subjects and HCPs regardless of the study group have to be fully informed about the background and procedures of the study prior to the start. As such, in the ProValue studies,
participants in the control group and HCPs were fully aware of the hypothesis that an iPDM and structured SMBG were expected to improve glycemic control. Participants randomized to the control group might therefore, whether or not intentionally, have sought for a comparable treatment or intensified their therapy on their own [31, 35]. Because of the detailed assessment of therapy adjustments and recommendations of HCPs in the ProValue studies, the main triggers for behavior changes that were identified for the subjects in the intervention group could also be detected among those in the control group [20]. Control group patients typically receive “standard of care” or “treatment as usual,” but these conditions are often less defined and monitored than the interventional treatment [29].

Standard care differs across countries, hospitals, and over time, depending on the respective health care provisions and updated guidelines and technologies that are introduced at variable rates. Especially in multicenter studies, the actual implementation might vary considerably between study sites and this cannot be controlled in cluster-randomized studies [36]. A clear definition of what is regarded as “standard” is essential for the validity of a study and should receive as much attention as the definition of the intervention. Mostly, patient care within a study is rather an enhanced standard of care for all the reasons discussed above. A meta-analysis of randomized control trials (RCTs) that investigated standard care conditions in control groups of behavior change studies in patients with diabetes showed that those control group patients that received a higher quality of standard care also showed larger improvements in study outcomes, thus reducing the effect size of the intervention [36].
Nevertheless, chronic disease management like diabetes therapy is complex and, like the intervention, standard of care cannot be fully standardized but has to be adapted to the individual patient and their compliance.

Alternative study designs

Due to recruitment and “contamination” problems in interventional trials requiring behavioral changes, the realization of standard RCTs may be difficult [23]. Alternatives to the standard RCT when designing a medical device studies that rely on behavioral changes may be considered. While the above-described aspects concern the detailed implementation of a study, some variations in the general design might be considered with regard to the effect size, which was often observed to be lower than expected.

If control group effects are expected, it is essential to identify the particular reasons or triggers for behavior changes that may occur. Once identified, study procedures can be adjusted to avoid them or to even include them into the intervention. A pilot phase or study is indispensable to identify such factors and should therefore be included, especially if a large trial is planned. Therefore, more and more studies consider the additional effort of a pilot trial [7, 8, 11, 37, 38].

As the Hawthorne effect is described to be temporary and of relatively short duration [39], one approach towards a reduction of influencing the behavior of the subjects in the control group is to add one or several pretest periods to the study design [40, 41]. This means additional data collection before and after the pretest period, without an interventional treatment in any of the groups. Randomization and initiation of the intervention starts after this period using data obtained after the pretest as baseline data. Because it is expected that the majority of improvements induced by study effects occur between the first and the second data collection, the data used for the assessment of study outcomes will not be impaired, or at least less. However, the inclusion of a pretest period is cost and time expensive and might require a pilot study to determine an adequate duration. For STeP and the ProValue studies, a 3-month pretest period would have been sufficient, as the results indicate the strongest control group effects within the first 3 months of the study. Nevertheless, because these studies were accompanied by a lot of preparations for intervention group sites, such as training sessions, a postponement of randomization procedures would have interrupted the whole study flow.

One possibility for control conditions in RCTs is using a waitlist control [42]. Subjects of the control group that are on a waiting list, i.e., they expect to receive the active intervention at a later time point, have been shown to improve less than patients that receive only standard of care throughout the whole study [29]. A waiting control group could therefore be a more efficient way to influence the effect size than an inactive control group.

Other options include a third study arm to control for enhanced standard of care and study effects. Schwartz et al. proposed a design in which one arm receives the intervention, while the control condition has two arms, each with a crossover between a waiting list with standard of care and receiving the intervention [43]. Several data collection points are required for such a design. The crossover design reduces the heterogeneity within a group due to individually tailored implementation of the intervention, increasing statistical efficiency. Nevertheless, feasibility of a crossover depends on the kind of intervention and the expected long-term effects. Additionally, inclusion of further study arms reduces statistical power, and accordingly, it requires the inclusion of more subjects which also increases financial cost and study duration [41].

In this regard, retrospective data collection could be a feasible option, but only if required data are limited to standard assessments during usual patient visits, as expected when standard of care is claimed for control group subjects.

Use of historical controls, i.e., data assessed in other independent studies that already were conducted, is another promising option if study effects shall be reduced [44, 45]. In addition, with the use of historical controls, more resources become available for the intervention arm (which could be used for a larger sample size and therefore an increased power). Identification of a suitable control data set for the respective objective, however, is challenging, as well as the correct use of these data. In addition, the progress in treatment standards, assessment technologies, and other factors over time have to be considered.

A better separation of intervention and control group might be reached by using two separate protocols for the two groups. Consequently, all other participants such as CRAs should be exclusively assigned to one of the groups. The ProValue studies already worked with two protocols, but those were divided by the type of practice of the study sites rather than by study groups. A separate control group protocol would on the one hand enable a clear definition of “standard of care” and on the other hand allow a reduction of procedures in the control group to an absolute minimum. This applies not only to contacts between subjects and HCPs, but also between HCPs and further study staff. In addition, suitably designed informed consent forms should avoid inclusion of interventional aspects.

To prevent patients from consenting to therapy forms they may not get, a two-stage randomization could be another option. Accordingly, all patients give consent for follow-up first. An additional consent for study intervention is only provided if resources become available for the intervention arm (which could be used for a larger sample size and therefore an increased power). Identification of a suitable control data set for the respective objective, however, is challenging, as well as the correct use of these data. In addition, the progress in treatment standards, assessment technologies, and other factors over time have to be considered.

To prevent patients from consenting to therapy forms they may not get, a two-stage randomization could be another option. Accordingly, all patients give consent for follow-up first. An additional consent for study intervention is only provided to a randomly selected sample. Thus, patients randomized to the control group do not feel disadvantaged not receiving the intervention [46]. However, ethical concerns remain because there is only a personal consent to patient’s treatment and no full consent to the project from all patients [23, 46].
Adaptive study designs are becoming more and more common, however, not yet in medical device studies, but rather in drug studies, as adaptive designs are in particular effective in investigating dose-response relationships. Nevertheless, some of the several different approaches might also be used for medical device studies. Adaptive design means that procedures or conditions of a study are modified during the ongoing study based on results from interim analyses. However, these changes have to be planned and defined in advance [47, 48]. Adaptations include, e.g., randomization based on baseline data or sample size re-estimation to ensure the desired power. Implementation of adequate adaptations in studies including behavioral change has yet to be investigated. Nonetheless, such an approach could reduce the necessity of a separate pilot study and combine the exploratory and confirmatory stages of an investigation in one single study [38, 49]. Performance of an underpowered trial may furthermore be prevented [47]. In addition, it might be a better reflection of clinical practice if those patients that prove to be compliant and susceptible for an intervention are selected. Considerations about whether or not introducing new therapeutic options (they be behavioral changes and/or diagnostic/treatment options) are usually made by HCPs based on their experiences with the respective patients.

Conclusion
Based on experiences from the STeP and ProValue studies, several crucial aspects have to be considered in medical device studies when using interventions that rely on changes in behavior of study participants and their HCPs to achieve an effective implementation and significant results.

The article summarizes experiences gained from the three studies and provides suggestions for the implementation of other studies with similar medical devices.

In particular, definition of control group conditions and an integrative support of the intervention group have to be included. Improvements in the control group may reduce effect sizes and limit statistical significance; therefore, alternatives to the traditional RCT, like pretest periods or separate study protocols, are worth to be considered. As there is no ideal design for such studies, integration of experiences from other studies is essential to achieve the best possible study outcome.

Abbreviations
CGM: Continuous glucose monitoring; CRAs: Clinical research associates; HCPs: Health care professionals; iPDm: Integrated Personalized Diabetes Management; RCTs: Randomized controlled trials; SMBG: Self-monitoring of blood glucose; STeP: Structured Testing Program

Acknowledgements
The authors would like to thank Guido Freckmann for the support in writing the manuscript.

Authors’ contributions
BP, IV, BP, and ND were involved in the concept and design of the STeP and ProValue studies. DW performed a literature search and wrote the first draft of the manuscript, and all authors contributed to subsequent revisions of the manuscript and approved the final version.

Funding
Scientific writing was funded by Roche Diabetes Care. The reported STeP study was funded by Roche Diabetes Care. Roche Diabetes Care was involved in the concept and design of the reported STeP and ProValue studies. Roche Diabetes Care contributed to subsequent revisions of the manuscript and approved the final version.

Availability of data and materials
Not applicable

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
DW and SB are employees of the IfDT (Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany), which carries out clinical studies on the evaluation of BG meters and medical devices for diabetes therapy on its own initiative and on behalf of various companies. IfDT has received speakers’ honoraria or consulting fees from Abbott, Ascensia, Dexcom, LifeScan, Menarini Diagnostics, Metromed Health, Novo Nordisk, Roche, Sanofi, Sensile, and Ypsomed. BP, IV, BP, and ND are employees of Roche Diabetes Care. LH is a consultant for a number of companies that develop novel diagnostic and therapeutic options for diabetes treatment, e.g., Roche Diabetes Care, Becton Dickinson, Lifecare, and Berlin-Chemie. LH is a shareholder of the Profil Institut für Stoffwechselforschung, Neuss, Germany, and ProSciento, San Diego, USA.

Author details
1Roche Diabetes Care GmbH, Mannheim, Germany. 2Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Lise-Meitner-Strasse 8/2, 89081 Ulm, Germany. 3Science Consulting in Diabetes GmbH, Neuss, Germany.

Received: 21 January 2020 Accepted: 31 December 2020
Published online: 18 January 2021

References
1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
2. Goyal S, Lewis G, Yu C, Rotondi M, Seto E, Cafazzo JA. Evaluation of a behavioral mobile phone app intervention for the self-management of type 2 diabetes: randomized controlled trial protocol. JMIR Res Protoc. 2016;5:e174.
3. Polonsky WH, Fisher L, Schikman CH, et al. A structured self-monitoring of blood glucose approach in type 2 diabetes encourages more frequent, intensive, and effective physician interventions: results from the STeP study. Diabetes Technol Ther. 2011;13:797–802.
4. Scavini M, Bosi E, Ceriello A, et al. Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. Acta Diabetol. 2013;50:663–72.
5. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701.
6. Nishimura A, Harashima SI, Fujita Y, et al. Effects of structured testing versus routine testing of blood glucose in diabetes self-management: a randomized controlled trial. J Diabetes Complicat. 2017;31:228–33.
7. Taggart L, Truesdale M, Carey ME, et al. Pilot feasibility study examining a structured self-management diabetes education programme, DESMOND-ID, targeting HbA1c in adults with intellectual disabilities. Diabet Med. 2018;35:137–46.

8. Silva DD, Bosco AA. An educational program for insulin self-adjustment associated with structured self-monitoring of blood glucose significantly improves glycemic control in patients with type 2 diabetes mellitus after 12 weeks: a randomized, controlled pilot study. Diabetol Metab Syndr. 2015;7:2.

9. Williams JS, Lynch CP, Knapp RG, Egede LE. Technology-Enhanced Diabetes Education Study (TIDES) in African Americans with type 2 diabetes: study protocol for a randomized controlled trial. Trials. 2014;15:460.

10. Willis TA, Hartley S, Glidewell L, et al. Action to Support Practices Implement Research Evidence (ASPIRE): protocol for a cluster-randomised evaluation of adaptable implementation packages targeting ‘high impact’ clinical practice recommendations in general practice. Implement Sci. 2016;11:25.

11. Dobson WH, Whitaker R, Jiang Y, et al. Effectiveness of text message based, diabetes self-management support programme (SIMSBG): a two arm, parallel randomised controlled trial. BMJ. 2018;361:k1959.

12. Lynch CP, Williams JS, Ruggiero KJ, Knapp RG, Egede LE. Tablet-Aided Behavioral intervention Effect on Self-management Skills (TABLETS) for diabetes. Trials. 2016;17:157.

13. Wild SH, Hanley J, Lewis SC, et al. Supported telemonitoring and glycemic control in people with type 2 diabetes: the Telescot diabetes pragmatic multicenter randomized controlled trial. PLoS Med. 2016;13:e1002098.

14. Di Bartolo P, Nicolucci A, Cherubini V, Iafusco D, Scandapane M, Rossi MC. Young patients with type 1 diabetes poorly controlled and poorly compliant with self-monitoring of blood glucose: can technology help? Results of the i-NewTrend randomized clinical trial. Acta Diabetol. 2017;54:393–402.

15. Lalic NM, Lalic K, Jotic A, et al. The impact of structured self-monitoring of blood glucose combined with intensive education on HbA1c levels, hospitalizations, and quality-of-life parameters in insulin-treated patients with diabetes at primary care in Serbia the multicenter SPADA-EDU study. J Diabetes Sci Technol. 2017;11:746–52.

16. Agarwal P, Mukerji G, Desveaux L, et al. Mobile app for improved self-management of type 2 diabetes: multicenter pragmatic randomized controlled trial. JIMR Mhealth UeHealth. 2019;7:e10321.

17. Polonsky W, Fisher L, Schikman C, et al. The value of episodic, intensive blood glucose monitoring in non-insulin treated persons with type 2 diabetes: design of the Structured Testing Program (STeP) study, a cluster-randomised, clinical trial [NCT00674986]. BMC Fam Pract. 2010;11:37.

18. Kuzer B, Daenshel W, Daenshel J, et al. Integrated personalized diabetes management (PDM): design of the ProValue studies: prospective, cluster-randomized, controlled, intervention trials for evaluation of the effectiveness and benefit of PDM in patients with insulin-treated type 2 diabetes. J Diabetes Sci Technol. 2016;10:772–81.

19. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care. 2011;34:262–7.

20. Kuzer B, Daenshel W, Daenshel J, et al. Integrated personalized diabetes management improves glycemic control in patients with insulin-pump treated type 2 diabetes: results of the PDM-ProValue study program. Diabetes Res Clin Pract. 2018;144:200–12.

21. Bosi E, Scavini M, Cerello A, et al. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRSMA randomized trial. Diabetes Care. 2013;36:2887–94.

22. Gale EA, Beattie SD, Hu J, Kivisto V, Tan IH. Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes Care. 2007;30:2989–92.

23. Campbell R, Peters T, Grant C, Quality B, Dieppe P. Adapting the randomized consent (Zelen) design for trials of behavioural interventions for chronic disease: feasibility study. J Health Serv Res Policy. 2005;10:220–5.

24. Heinemann L. Future of diabetes technology. J Diabetes Sci Technol. 2017;11:1196–9.

25. Klonoff DC. Behavioral theory: the missing ingredient for digital health tools to change behavior and increase adherence. J Diabetes Sci Technol. 2019;13:276–81.

26. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1:189–99.

27. Reach G. Technology can improve adherence to long-term therapies? J Diabetes Sci Technol. 2009;3:492–9.

28. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.

29. Mohr DC, Spring B, Freedland KE, et al. The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychol Psychoth. 2009;78:275–84.

30. van Breukelen GJ, Candel MJWM. Efficiency loss because of varying cluster size in cluster randomized trials is smaller than literature suggests. Stat Med. 2012;31:397–400.

31. Abraham MB, Nicholas JA, Crone M, Ly T, Davis EA, Jones TW. The importance of the Hawthorne effect on psychological outcomes unveiled in a randomized controlled trial of diabetes technology. J Diabetes Sci Technol. 2018;12:735–6.

32. Campbell BF, Sengupta S, Santos C, Lorig KR. Balanced incomplete block design: description, case study, and implications for practice. Health Educ Q. 1995;22:201–10.

33. Wilding S, Corrier M, Sandberg T, et al. The question-behaviour effect: a theoretical and methodological review and meta-analysis. Eur Rev Soc Psychol. 2016;27:196–230.

34. Tai MC-T. Deception and informed consent in social, behavioral, and educational research (SBER). Tzu Chi Med J. 2012;42:218–22.

35. Byrd-Bredbenner C, Wu F, Spaccavento K, Quick V, Martin-Biggers J, Zhang Y. Systematic review of control groups in nutrition education intervention research. Int J Behav Nutr Phys Act. 2017;14:91.

36. Aylng K, Briery S, Johnson B, Heller S, Eiser C. How standard is standard care? Exploring control group outcomes in behaviour change interventions for young people with type 1 diabetes. Psychol Health. 2015;30:885–103.

37. House A, Bryant L, Russell AM, et al. Managing with learning disability and diabetes: OK-Diabetes – a case-finding study and feasibility randomised controlled trial. Health Technol Assess (Winchester, England). 2018;22:1–328.

38. Karlsen B, Oftedal B, Stangeland Lie S, et al. Assessment of a web-based guided self-determination intervention for adults with type 2 diabetes in general practice: a study protocol. BMJ Open. 2016;6:e013026.

39. Cambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67:267–77.

40. Becker H, Roberts G, Volenec W. Explanations for improvement in both experimental and control groups. West J Nurs Res. 2003;25:746–55.

41. Eccles M, Grimshaw J, Campbell M, Ramsay C. Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual Saf Health Care. 2003;12:47–52.

42. Kim H, Park EM, Henry C, Ward SE, Song MK. Control conditions that are neither usual care nor no treatment in randomized trials of psychoeducational palliative care interventions: a systematic review. Am J Hosp Palliat Care. 2019;36:339–47.

43. Schwartz CE, Chesney MA, Irvine MJ, Keefe FJ. The control group dilemma in clinical research: applications for psychosocial and behavioral medicine trials. Psychosom Med. 1997;59:362–71.

44. Viele K, Berry S, Neuenanswender B, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13:341–54.

45. Galwey NW. Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion? Stat Med. 2017;36:899–916.

46. Stott DJ, Langhorne P, Rodgers H. Informed consent: Two stage randomisation and consent would overcome many problems. BMJ (Clinical research ed). 1997;315:257–52.

47. Pallmann P, Bedding AW, Choodari-Oskooei B, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29.

48. Chow SC. Adaptive clinical trial design. Annu Rev Med. 2014;65:405–15.

49. Wang SJ, Hung HM, O’Neill P. Paradigms for adaptive statistical information designs practical experiences and strategies. Stat Med. 2012;31:3011–23.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.